Aurobindo gets USFDA nod for Clindamycin Hydrochloride
MUMBAI, Aug 27 (Reuters) - Aurobindo Pharma Ltd (ARBN.BO: Quote, Profile, Research) said on Thursday it has received approval from the US Food and Drug Administration for Clindamycin Hydrochloride Capsules.
The drug, which is a generic equivalent of Cleocin Hydrochloride capsules, is used to treat certain bacterial infections and has a market size of about $55 million, the company said in a statement to the stock exchange.
(Reporting by Jasudha Kirpalani; Editing by Ramya Venugopal)
© Thomson Reuters 2010 All rights reserved
Economy seen growing at 7.2 pct in FY10 - govt
The forecast reinforces the possibility that the government may start to unwind its fiscal stimulus in the budget. Full Article
Greek crisis sets euro zone enlargement back
The Greek debt crisis has dealt a setback to prospects of enlarging the euro zone by highlighting the difficulties of managing the single currency area. Full Article
India
US
UK
